Centessa Pharmaceuticals (CNTA) Stock Statistics & Valuation Metrics

Centessa Pharmaceuticals has a market cap or net worth of $2.25B. The enterprise value is $1.62B.

Centessa Pharmaceuticals has 134,073,440 shares outstanding. The number of shares has decreased by -2.65% in one year.

Centessa Pharmaceuticals’s return on equity (ROE) is -0.59 and return on invested capital (ROIC) is -39.23%.

The current PE Ratio of Centessa Pharmaceuticals is ―. Centessa Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Centessa Pharmaceuticals had revenue of 0.00 and earned -235.76M in profits. Earnings per share was -2.06.

In the last 12 months, operating cash flow was -143.89M and capital expenditures -160.00K, giving a free cash flow of -144.05M billion.

Centessa Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Centessa Pharmaceuticals upcoming earnings date is Nov 17, 2025, Before Open (Confirmed).

Centessa Pharmaceuticals as a current ratio of 9.25, with Debt / Equity ratio of 30.55%

In the past 12 months, Centessa Pharmaceuticals has paid 2.84M in taxes.

Centessa Pharmaceuticals EV to EBITDA ratio is -7.44, with an EV/FCF ratio of -11.62.

Centessa Pharmaceuticals has $250.72M in cash and marketable securities with $118.14M in debt, giving a net cash position of -$132.58M billion.

Gross margin is 97.36%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Centessa Pharmaceuticals is $34.43, which is 11.43% higher than the current price. The consensus rating is Strong Buy